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Abstract 
 
     Being diagnosed with a diet-related health condition like high blood cholesterol 
might compel an individual to choose a healthier diet, thereby reducing disease 
risks. Adding the option of medication, like statins, makes the direction of diet-
quality choices theoretically ambiguous. This study estimates how dietary quality 
correlates with high cholesterol diagnoses and medicine use. Results indicate that 
individuals diagnosed with high cholesterol consume less cholesterol, fat, and 
saturated fat, and smoke less. However, using cholesterol-lowering drugs is 
correlated with increased fat and saturated fat intake, and larger waist size, after 
accounting for the endogeneity of choosing to use medicine. Findings highlight the 
inelasticity of diet choices. 
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1 Introduction  
 
Worldwide, nearly 1.6 billion adults were overweight and over 400 million were obese 
in 2005. By 2015, it is projected that these numbers will rise to 2.3 billion overweight 
and 700 million obese (World Health Organization, 2006). Such trends are troubling, 
as scientific evidence indicates obesity is associated with increased risk of premature 
death, type II diabetes, heart disease, stroke, hypertension, gallbladder disease, 
osteoarthritis, and many other maladies (U.S. Department of Health and Human 
Services, Public Health Service, Office of the Surgeon General, 2001). This 
widespread prevalence of obesity and diet-related illnesses begs the question why so 
many people are putting themselves at risk of serious illnesses. 
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The problem posed by many behaviours that jeopardize health is that such 
behaviour is itself often enjoyable. While the risks of smoking are well-known, the 
satisfaction from nicotine makes it hard for many to break the habit. And though a diet 
low in salt, cholesterol and saturated fat may promote cardiovascular fitness, many 
choose taste and convenience over long-term health. The enjoyment of such risky 
behaviours conceivably could have a major impact on the realized benefits from 
medical advances, safety enhancements to consumer goods or government-mandated 
safety regulations because individuals could respond by making riskier choices 
(offsetting behaviour), thus attenuating the direct health benefits of these 
improvements. 
The question addressed in this study is whether or not technological change 
induces risky choices for chronic health conditions that are manageable with diet and 
lifestyle choices. We estimate the extent to which people diagnosed with high 
cholesterol manage the potential health risks by changing their diet and how much 
they compromise diet quality when they also use cholesterol-lowering statin drugs.  
Thus for this study, we develop a theoretical model to show that if consumers 
treat diet and medication as substitutes in producing good health, consumers are 
unlikely to realize all the health benefits possible from diet and medication. For 
empirical support of our hypotheses, we use data from the National Health and 
Nutrition Examination Survey (NHANES) 1999-2000, 2001-2002, and 2003-2004, 
which contain detailed information on dietary intake, medical conditions and whether 
an individual takes medication for such conditions. These data are used to estimate 
how differences in dietary quality correlate with whether or not an individual has been 
diagnosed with high cholesterol, and whether or not an individual uses medication to 
manage his or her health condition.  
 
2 Background 
 
Peltzman (1975) initiated empirical work on offsetting behaviour, demonstrating that 
U.S. government-mandated automobile safety equipment had little impact on highway 
safety. Mandated safety equipment probably made cars safer for drivers and 
passengers, but simultaneously reduced the cost of reckless speed. Drivers responded 
by raising their “driving intensity,” leading to more accidents. A vast literature 
estimating the magnitude of offsetting behaviour and deaths and injuries followed 
Peltzman’s findings. (See Hause (2006), for findings related to traffic, workplace, and 
consumer product accidents).  
Conceivably, improvements in drug treatments could induce a “lulling effect,” 
(Viscusi, 1984). Kahn (1999) investigated a problem similar to ours—the diet and 
lifestyle choices diabetics made over a period in which drugs that help control blood 
sugar dramatically improved. His concern was that improved drugs could have made 
diabetics falsely think the drugs solved their health problems, reducing adherence to 
the diet regimes recommended to manage diabetes. The undesirable result would be 
additional complications of diabetes—heart disease, stroke, amputations, blindness, 
and renal failure. His empirical results showed no significant evidence of offsetting 
behaviour, but included the use of medication as an exogenous, explanatory variable. 
For modelling risky choices like driving intensity, this is a reasonable 
assumption, as safety equipment mandated by government regulation is arguably 
exogenous. And while using medication to treat diet-related illnesses can be viewed as 
a kind of safety equipment, pharmaceutical use is often a choice influenced by many 
of the same factors that influence diet quality. As such, treating pharmaceutical use as 
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an exogenous variable will bias its estimated effect. If an overall concern for health is 
positively correlated with the probability of taking medication to improve health, then 
any estimator that does not account for the simultaneous nature of these choices will 
upwardly bias the estimated effect of taking medication. The other parameter 
estimates will be biased as well. 
For this study, we focus on high blood cholesterol, which is a major risk factor 
for heart disease (U.S. Department of Health and Human Services, Centers for Disease 
Control and Prevention, 2007). Coronary heart disease is the leading cause of 
morbidity and mortality in the United States, estimated to cause 481,000 deaths each 
year and require 11.8 million hospital days of care per year. It is the leading cause of 
disability adjusted life years and is second only to injuries as a cause of life-years lost 
(Gross et al., 1999).  
However, high blood cholesterol is a modifiable risk factor. Dietary changes, 
increased physical activity, weight control, drug therapy, or a combination of these 
have been shown to lower cholesterol levels (U.S. Department of Health and Human 
Services, Centers for Disease Control and Prevention, 2007). Lowering cholesterol 
and other fats in the blood may help prevent medical problems caused by cholesterol 
clogging the blood vessels (Miller and Stagnitti, 2005) and substantially reduce health 
risks: a 10 percent decrease in total blood cholesterol can reduce the incidence of heart 
disease by as much as 30 percent (U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention, 2007).  
In recent years, individuals have demonstrated a growing interest in drug therapy 
as a means of lowering blood cholesterol. While there have been cholesterol-reducing 
drug therapies available for many years, the statin drugs are more effective at reducing 
cholesterol
1
 than older drugs (Pignone et al., 2001). Ranked by expenditures, the top 
two drugs in 2003 were cholesterol-reducing agents: Lipitor® (Atorvastatin calcium) 
and Zocor® (Simvastatin) (U.S. Department of Health and Human Services, Agency 
for Healthcare Research and Quality, 2006). 
 
3 Theoretical and Empirical Model 
 
One response to a diagnosis of high blood cholesterol could be to strictly follow 
doctor’s orders. However, desires for good health may compete against desires for 
familiar diets and lifestyle. These diet and lifestyle choices may be conditioned by a 
lifetime of habit as well as by family and community traditions. Thus, medication may 
be a substitute for diet and lifestyle changes as a means to reduce health risks because 
it lowers the health cost (increased probability of an adverse outcome) of failing to 
make diet and lifestyle changes. In this case, some offsetting behaviour is almost 
certain; the important question for forecasting a health outcome is how much 
offsetting behaviour will occur? If the protective effect of medication is assumed large 
while the pull of the familiar diet and lifestyle is strong, major diet and lifestyle 
changes are unlikely.  
                                           
1
 There are several patterns of blood lipids that are important risk factors for coronary heart 
disease. These include elevated total cholesterol (usually with a threshold of 240mg/dl), 
elevated low-density lipoprotein cholesterol (LDL), and low levels of high-density lipoprotein 
cholesterol (HDL) (Pignone et al., 2001). For ease of exposition, we refer to this class of health 
conditions as high cholesterol and drug therapy as cholesterol-reducing.  
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For a more precise understanding of how consumers will respond to a diagnosis 
of high blood cholesterol, we employ a straightforward utility maximization problem. 
We assume individuals gain utility from risky behaviours (R), their own health (H) 
and all other goods (C). We define H as a perceived health production function and 
assume that individuals manage health through behaviours and medication (M). For 
simplicity, risky behaviours over which utility is defined are selecting a nutritionally 
poor diet and having a sedentary lifestyle. Offsetting behaviour flows directly from 
utility maximizing behaviour. As long as good health enters the utility function, the 
health-compromising (undesirable) attributes of risky behaviours also influence the 
utility maximization. Also, how highly an individual assesses his current level of 
health is driven by η, a parameter that represents medical evidence of a current health 
condition. For example, someone who was told that he had high blood cholesterol 
would assess his health at a lower level than before learning this news. Thus, there is 
an inverse relationship between H and η. Other goods (C) are assumed to have no 
direct impact on health. 
Maximizing utility subject to the income constraint and to the health production 
function can be written in standard form as 
  
 
where I is income, RP  and MP  are the prices for risky behaviours and medication, and 
for simplicity, the price of all other goods, C, is defined as the numeraire. First order 
conditions imply the following equality: 
 
 
                                                                                                                   
 
That is, the marginal rate of substitution between risky behaviours and 
pharmaceuticals that offset the health cost of risky behaviours is equal to the price 
ratio. The marginal utility of risky behaviours is a net concept as it includes the direct 
benefits as well as the health cost. 
Rewriting equation (2) as 
 
                                                                                                                   
 
and invoking the implicit function rule yields a relation between risky behaviour and 
perceived health status. 
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Our goal is to sign the derivative 
R



 — the change in risky behaviour given bad 
health news — for a typical individual, not all mathematically possible utility and 
production functions. We make conventional assumptions that 
 
 
 
  
 
That is, the marginal utilities are positive, and utility and production functions are 
concave. The marginal product of medicine is positive, but risky behaviours that bring 
enjoyment are defined to be unhealthy and information about health is assumed to be 
bad news, reducing perceived health status. 
 
 
 
 
Conventional utility and production function assumptions, however, are not sufficient 
to sign the derivative. In addition, we assume that 0.RH HRU U   That is, bad 
behaviour can be more rewarding when in better health. The equality also allows for 
the possibility that the rewards from bad behaviour are independent of health status. 
We assume 0, 0, 0.M R MR RMH H H H      Medicine becomes more 
important to health when health news is bad (or does not change), risky behaviours 
compromise health more (or equally) when health news is bad, and the efficacy of 
medicine is independent of poor diet and lifestyle choices. For example, we assume 
that a statin drug’s marginal impact on health is unaffected by one’s level of physical 
activity. Under these conditions, 
R



is negative, indicating that the net effect of bad 
health news is to reduce risky behaviours that compromise health. Individuals will 
adjust to bad health news by making healthier diet and lifestyle choices. 
To determine the impact of medication on risky behaviours, we use the following 
relation between pharmaceutical use and risky behaviour:  
 
 
 
 
 
Under the same conditions imposed on partial derivatives and cross partials, 
R
M
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positive. In effect, medicine makes it easier to return to risky behaviours that 
compromise health. The impact of making health benefits possible from 
pharmaceuticals means that many will forego some, if not all, of the possible health 
benefits. Some individuals will find they improve their overall well-being by taking 
medication while also choosing diets and lifestyles that are less healthy than they 
would choose if they had to rely on diet and lifestyle alone to manage a diet-related 
disease. 
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This analysis of partial and cross partial derivatives yields three hypotheses that 
can be tested empirically:  
 
 There is a negative relationship between being made aware of a health 
condition, such as high blood cholesterol, and specific behaviours, such 
as choosing to eat an unhealthy diet; 
 
 There is a positive relationship between taking medication for a health 
condition and these same risky behaviours; and  
 
 The effect of medication on increasing risky behaviours may offset the 
reductive effect of better health awareness. 
 
Empirically, our model suggests that an individual’s chosen level of risky behaviours 
( iR ) can be modelled as a function of income, prices, and health status ( iH ), which is 
determined by behaviours, awareness of a health condition ( i ), and use of prescribed 
medication ( iM ). This specification illuminates the simultaneous nature of 
behavioural choices, medication and health status. The empirical model can be written 
as: 
 
 
 
where iX  is a vector of exogenous explanatory variables that relate to individual 
behavioural choices, i  indicates whether or not an individual is aware of a specific 
health condition, and ie  is a random disturbance term. Among individuals who have 
been diagnosed with a health-condition, their behavioural choices can be modelled as 
follows 
 
 
 
where 
i
M  indicates whether or not an individual takes medication for this condition 
and iZ  is a vector of exogenous explanatory variables relating to whether or not an 
individual chooses to manage his health condition through medication, and i  is a 
random disturbance term. 
An estimation approach that does not explicitly address that individuals with a 
health condition can use both medication and behavioural modification to manage 
health will produce biased estimates of the relationship between explanatory variables 
and observed behaviours. Thus, among individuals diagnosed with high cholesterol, 
we estimate each behavioural choice equation simultaneously with a treatment effect. 
In the first equation, we run a probit regression to estimate whether an individual 
chooses to manage health via medication. In the second equation, we estimate how the 
choice to take medication correlates with differences in diet and activity choices 
recommended to control levels of cholesterol. Following the estimation strategy of 
Lakdawalla et al. (2006), to allow for correlation between use of medication and risky 
'
i i i i
R X e     (8) 
,
'
i D i i i i
R X M e       
i i i
M Z    
(9a) 
(9b) 
L. Mancino & F. Kuchler, Journal of Choice Modelling, 2(1), pp. 51-64   
 
57 
 
behaviours, we assume that the errors ie  and i  are correlated and jointly distributed 
as bivariate normal. We use maximum likelihood to estimate this joint model. To 
obtain robust variance estimates, we use the “treatreg” command in STATA 9.0, 
controlling for survey sample weights and inter-strata variation. 
 
4 Data 
 
This study uses recent data sets from the National Health and Nutrition Examination 
Survey 1999-2000, 2001-2002, and 2003-2004 (for simplicity NHANES 1999-2004). 
The NHANES data have been collected annually through the Centers for Disease 
Control and Prevention via the National Center for Health Statistics since 1999. Each 
year approximately 5,000 civilian, non-institutionalised persons in the United States 
receive a thorough medical examination, provide a 24-hour dietary recall, and answer 
questions related to health behaviours, such as dieting, physical activity, alcohol 
consumption, and cigarette smoking. This survey is designed to be nationally 
representative and over-samples African-Americans, Mexican-Americans and 
individuals with low income (United States Department of Health and Human 
Services, Centers for Disease Control and Prevention, National Center for Health 
Statistics, 2006). We limit our analysis to adults, aged twenty and older. Individuals 
under the age of 20 were not asked if they were diagnosed with high cholesterol. We 
also exclude pregnant and lactating women from our analysis since their dietary needs 
differ significantly from the rest of the population. In total, our sample includes 
observations on 11,446 individuals. 
In general, individuals with high cholesterol are instructed to choose a diet that is 
low in cholesterol, fat, and saturated fat. They are told to quit smoking and maintain a 
healthy bodyweight. We therefore created several dependent variables based on these 
recommendations (Table 1). For cholesterol, fat, and saturated fat, the dependent 
variable is total daily consumption of each nutrient per day divided by that 
individual’s total daily energy intake (calculated from 24-hour dietary recall reports).  
For cigarettes, the dependent variable is constructed as the number of cigarettes 
consumed on average. As a measure of excess bodyweight, we use an individual’s 
measured waist circumference relative to the gender specific overweight 
classification—88 centimetres for women and 102 centimetres for men (U.S. 
Department of Health and Human Services, National Institutes of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases, 2004). We chose this 
measure over body mass index (BMI), or weight adjusted for height, because BMI 
measures do not distinguish between muscle and total fat. 
The explanatory variables used in our econometric estimation are also described 
in Table 1. We present the analysis of income differences in terms of a households’ 
income-to-poverty ratio (PIR)—the ratio of a household’s income relative to the 
poverty threshold, given the size of a family. We also control for an individual’s level 
of education (education up to and including high school or more than high school) 
because this variable is highly predictive of income and health knowledge.
2
  
                                           
2
 Similar to other national surveys on dietary intake, NHANES does not collect information on 
food prices respondents pay or their food expenditures. 
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Table 1: Summary Statistics 
 
Variable Name                                    Definition and units Mean Std. Err. 
Dependent variables 
Cholesterol Cholesterol consumption adjusted for caloric intake: 100 × daily cholesterol 
intake (mg)/daily caloric intake  
12.93 0.19 
Total fat Total fat share of calories: 100 × 9 × daily fat intake (g)/daily caloric intake  33.50 0.21 
Saturated fat Saturated fat share of calories: 100 × 9 × daily saturated fat intake (g)/daily 
caloric intake  
10.92 0.10 
Cigarettes Average daily cigarette intake 3.07 0.20 
Waist Ratio of waist circumference (cm) to gender- specific overweight classification 
(88 cm for women, 102 cm for men) 
1.00 0.00 
Explanatory variables for risky behaviors 
PIR Poverty Index Ratio: Household income/poverty line for household size 3.29 0.06 
More than high school 1 if individual went to school beyond high school; zero otherwise 0.64 0.01 
Age Age in years 44.41 0.41 
Female 1 if female; zero otherwise 0.48 0.01 
Black, Non-Hispanic 1 if black, non-Hispanic; 0 otherwise 0.09 0.01 
Hispanic 1 if Hispanic; 0 otherwise 0.10 0.01 
Other Ethnicity 1 if other ethnicity; 0 otherwise 0.04 0.01 
Spanish 1 if Spanish is the primary language spoken at home; zero otherwise 0.04 0.01 
Other language 1 if neither English nor Spanish are the primary languages spoken at home; zero 
otherwise 
0.04 0.01 
Other health condition 1 if individual has ever been diagnosed with diabetes, heart failure, coronary 
heart disease, heart attack, or stroke; zero otherwise 
0.11 0.01 
Diagnosed with high 
cholesterol 
1 if individual has been diagnosed with high cholesterol; zero otherwise 0.26 0.01 
Undiagnosed, but 
cholesterol high 
1 if individual has not been diagnosed with high cholesterol, but LDL measures 
160 mg/DL or above; zero otherwise 
0.20 0.01 
Treatment variable 
Medication 1 if taking cholesterol-lowering medication; zero otherwise 0.10 0.01 
Instrumental variables for medication 
Insurance 1 if individual has health insurance; zero otherwise 0.84 0.01 
Relative with 
hypertension 
1 if relative has hypertension; zero otherwise 0.17 0.01 
Relative with angina 1 if relative has angina; zero otherwise 0.35 0.01 
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We account for systematic differences in food demand. For example, two 
individuals’ energy requirements may differ because of age and gender. Cultural 
norms and level of acculturation also have an influence on diet characteristics (Aldrich 
and Variyam, 2000). We attempt to capture these through an individual’s reported  
ethnicity and whether a language other than English is considered to be the 
respondent’s primary language. 
Our theoretical model predicts that being aware of a health condition will 
influence risk-taking behaviour. We define an individual as being diagnosed with high 
cholesterol if, in the questionnaire regarding medical conditions, the respondent 
indicates that he or she has been diagnosed with the condition. We include a dummy 
variable to indicate if that individual has any other health conditions, such as diabetes, 
coronary heart disease, and angina or if that person had a past heart attack or stroke, as 
that could cause him to change risky behaviours. We include a variable for individuals 
who indicate that they have not been diagnosed with high cholesterol but who have 
cholesterol levels that put them at risk: levels of low density lipid (LDL) cholesterol--
in excess of 160 mg/dL (American Heart Association, 2006).
3
 
To identify whether or not taking medication is correlated with offsetting 
behaviour, we control for the endogeneity of this choice by first using instrumental 
variables to estimate the choice to take medication. One instrument available in this 
data set is whether or not any blood relatives have been diagnosed with related health 
conditions. A blood relative’s health is arguably exogenous. We have very little 
control over whether a grandparent has a particular health condition. However, such 
conditions may be highly correlated with our own health and level of health 
information; our family’s health history is a strong predictor of our own health and 
watching a family member struggle with ill health may provide motivation to adopt 
healthier practices. Thus, as instruments, we use whether a respondent had any blood 
relatives who had been diagnosed with either angina or hypertension. Prices of 
medication could also serve as additional instruments (Park and Davis, 2001). As a 
proxy for prices, we use whether an individual currently has health insurance. 
 
5 Results 
 
For each dietary choice and behaviour, we present the results of both the OLS and 
treatment effects estimations for the entire NHANES sample (Table 2). These results 
can be interpreted to answer whether being diagnosed with high cholesterol compels 
an individual to reduce risky behaviours. We are also able to test whether the subset 
that have been diagnosed with high blood cholesterol behave differently from those 
who have high blood cholesterol but have not been so diagnosed. This comparison is 
indicative of a behavioural change; past diet dietary choices of those diagnosed with 
high cholesterol are likely to be more similar to those with undiagnosed high 
cholesterol than to those who have healthy blood cholesterol levels. 
                                           
3
 The American Heart Association’ website states that LDL cholesterol level greatly affects 
risk of heart attack and stroke, and is a better gauge of risk than total blood cholesterol. 
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Table 2: OLS Estimation Results--Effect of risk awareness on risk behaviours 
 
  Cholesterol Total Fat Saturated Fat Cigarettes Waist 
Explanatory variables  
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Constant  8.37 (8.26) 26.98 (27.63) 10.34 (22.39) 4.92 (5.75) 68.14 (36.08) 
PIR  0.03 (0.30) 0.11 (1.15) 0.00 (-0.07) -0.76 (-10.05) -0.8 (-5.63) 
More than high school -0.38 (-0.19) -0.07 (-0.21) -0.20 (-1.79) -2.5 (-10.63) -0.52 (-1.19) 
Age  0.19 (4.13) 0.25 (5.51) 0.04 (2.33) 0.29 (8.22) 0.73 (8.75) 
Age
2
  0.00 (-3.00) 0.00 (-5.44) 0.00 (-2.82) 0.00 (-10.07) -0.01 (-8.11) 
Female  -0.54 (-2.25) 0.48 (2.14) 0.08 (0.69) -1.19 (-5.33) 8.33 (16.41) 
Black, Non-Hispanic 1.93 (5.33) -0.63 (-1.75) -0.90 (-5.94) -2.49 (-8.23) 1.82 (3.57) 
Hispanic  1.49 (2.64) -0.61 (-1.49) -0.39 (-1.69) -2.94 (-6.87) -0.28 (-0.47) 
Other Ethnicity -0.73 (-0.85) -2.82 (-2.31) -1.55 (-3.60) -2.05 (-3.61) -3.69 (-2.39) 
Spanish  0.51 (0.85) -3.30 (-5.29) -1.49 (-5.60) -2.94 (-7.32) -3.02 (-3.21) 
Other language 0.32 (0.42) -4.68 (-5.45) -1.58 (-4.48) -0.87 (-1.64) -5.6 (-4.31) 
Other health condition 1.47 (3.61) 0.5 (1.22) 0.14 (1.17) 1.24 (3.44) 6.08 (7.27) 
Undiagnosed, but cholesterol high 0.44 (1.72)
†
 0.43 (1.52)
†
 0.42 (3.87)
†
 1.42 (4.24)
†
 6.96 (13.35) 
Diagnosed with high cholesterol -0.33 (-1.03) -0.19 (-0.60) 0.01 (0.11) -0.12 (-0.44) 7.49 (10.16) 
Model Fit 
R
2
  0.02 0.04 0.03 0.09 0.19 
N  10865 10865 10865 10820 10542 
† Can reject the hypothesis that the coefficients for diagnosed and undiagnosed are equal using 5% level of significance
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Tests for differences among coefficients (α = 0.05) shows that compared to those 
who have high cholesterol but have not been diagnosed, those who have been 
diagnosed report a lesser degree of some risky dietary and lifestyle choices. On 
average, an individual who consumed 2200 calories a day, ate approximately 18 fewer 
milligrams of cholesterol and about one less gram of saturated fat per day. The 
diagnosed also smoke significantly fewer cigarettes than those who have high levels of 
cholesterol that have not been diagnosed. These findings suggest that high blood 
cholesterol diagnoses do induce behavioural changes the public health community 
recommends. Findings also indicate no difference in waist size between the diagnosed 
and undiagnosed. Thus, there is no evidence that waist size is leading physicians to 
test for high cholesterol. 
The main hypothesis we want to test is that taking medication to manage health 
may cause an individual to increase risky behaviour and may even offset the effect of 
increased awareness about the ill-health effects of risky diet and lifestyle choices 
(Table 3). While intake of cholesterol and cigarette consumption do not increase, our 
results indicate that when people diagnosed with high blood cholesterol choose 
medication they also consume higher amounts of total fats and saturated fat. Again 
assuming 2200 calories per day, an individual who is diagnosed with high cholesterol 
and takes medication for this condition is estimated to eat roughly about 18 more 
grams of total fat and 12 more grams of saturated fat, respectively.
4
 Their waist sizes 
are also significantly higher. Among those taking cholesterol reducing medication, 
waist circumferences are estimated to be roughly 16 and 12 centimetres larger for men 
and women. Thus, these estimates far outweigh the reductions associated with being 
diagnosed with high cholesterol and provide evidence of offsetting behaviour. Even 
when armed with the knowledge of both how and why to adopt a healthier lifestyle, 
many individuals choose not to make significant changes. 
First stage results show support for our hypothesis that choosing to use 
medication is significantly and positively correlated with having a relative with 
hypertension. Use of medication is significantly and negatively associated with 
education, being a female, and having any other health condition (Table 3).  
 
6 Discussion 
 
The worldwide increasing prevalence of overweight and obesity, along with diet-
related illnesses, suggests there must be something that compensates for accepting 
such risks. Such dietary problems are becoming increasingly more common 
throughout developed countries. Given these strong preferences, the task in store for 
the public health community—changing individuals’ diets—is extremely difficult. 
Here, we offer a quantitative perspective on just how difficult it will be to realize a 
substantial improvement. We focus attention on the subset of consumers who have 
strong incentives to choose a healthy diet, those who have been told they have high 
levels of serum cholesterol, and show that they resist change. 
                                           
4
 There are many ways these extra nutrients can be derived from additional foods. Only a few 
individual foods yield these particular proportions of fat and saturated fat. The extra fat and 
saturated fat could be realized with an extra 2 tablespoons of butter or an extra one-fourth cup 
of cream cheese every day. 
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Table 3: Treatment Effect Estimation Results--Effect of medication on risk behaviours 
 
 Cholesterol Total Fat Saturated Fat Cigarettes Waist 
Explanatory variables 
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Estimated 
Parameter (t-stat.) 
Constant 8.30 (2.12) 32.31 (11.49) 13.47 (10.88) -0.46 (-0.24) 79.11 (11.88) 
PIR 0.01 (0.08) -0.18 (-0.87) -0.05 (-0.39) -0.76 (-4.23) -0.81 (-2.91) 
More than high school -0.63 (-0.99) 0.23 (0.40)  0.11 (0.31) -1.82 (-3.78) 0.07 (0.06) 
Age 0.22 (1.34) 0.04 (0.28) -0.11 (-2.08) 0.46 (5.64) 0.51 (1.79) 
Age
2
 0.00 (-1.28) 0.00 (-1.12) 0.00 (0.84) 0.00 (-7.20) -0.01 (-2.62) 
Female -1.08 (-1.68) 1.11 (2.12) 0.62 (3.30) -0.42 (-1.06) 9.86 (11.21) 
Black, Non-Hispanic 2.50 (4.02) -1.02 (-1.51) -1.04 (-3.08) -2.47 (-4.91) 2.38 (1.88) 
Hispanic 2.08 (1.75) -1.78 (-2.12) -0.55 (-1.27) -1.76 (-2.40) -1.88 (-1.33) 
Other Ethnicity 1.15 (0.59) -3.51 (-1.25) -2.48 (-2.37) -3.81 (-5.79) -8.90 (-2.25) 
Spanish -1.17 (-0.68) -4.74 (-4.32) -2.14 (-4.08) -3.54 (-5.65) -2.06 (-1.34) 
Other language -1.64 (-1.26) -4.01 (-2.53) -1.45 (-1.90) 1.05 (0.86) -2.91 (-0.82) 
Other health condition 1.00 (1.06) -1.36 (-1.37) -0.89 (-2.34) 2.13 (3.09) 0.99 (0.57) 
Medication-treatment effect 0.12 (0.04) 7.22 (1.93) 4.86 (4.47) -3.14 (-1.46) 14.33 (2.58) 
Treatment effect: Explanatory variables 
Constant -4.15 (-6.42) -4.13 (-6.25) -3.80 (-5.96) -4.27 (-6.32) -4.02 (-5.75) 
PIR -0.03 (-1.02) -0.02 (-0.88) -0.02 (-0.65) -0.03 (-1.24) -0.03 (-1.14) 
More than high school -0.20 (-2.28) -0.22 (-2.44) -0.21 (-2.29) -0.20 (-2.26) -0.20 (-2.22) 
Age 0.12 (5.42) 0.12 (5.60) 0.11 (5.17) 0.12 (5.50) 0.11 (4.96) 
Age
2
 0.00 (-4.39) 0.00 (-4.57) 0.00 (-4.23) 0.00 (-4.51) 0.00 (-4.00) 
Female -0.27 (-4.80) -0.27 (-4.62) -0.27 (-4.23) -0.26 (-4.43) -0.26 (-4.28) 
Black, Non-Hispanic -0.06 (-0.76) -0.09 (-1.03) -0.05 (-0.67) -0.05 (-0.66) -0.10 (-1.33) 
Hispanic 0.06 (0.42) 0.06 (0.43) 0.10 (0.70) 0.07 (0.44) 0.08 (0.49) 
Other Ethnicity 0.31 (1.20) 0.24 (0.92) 0.25 (1.05) 0.30 (1.18) 0.27 (0.97) 
Spanish -0.12 (-0.62) -0.15 (-0.76) -0.16 (-0.87) -0.12 (-0.59) -0.14 (-0.72) 
Other language -0.16 (-0.81) -0.13 (-0.68) -0.16 (-0.81) -0.15 (-0.81) -0.15 (-0.74) 
Other health condition 0.59 (6.23) 0.60 (6.45) 0.59 (6.24) 0.59 (6.35) 0.63 (6.35) 
Insurance 0.40 (1.64) 0.35 (1.48) 0.34 (2.14) 0.48 (1.53) 0.41 (1.79) 
Relative with angina 0.06 (0.74) 0.00 (-0.08) -0.01 (-0.05) 0.05 (0.61) 0.07 (0.92) 
Relative with hypertension 0.16 (2.17) 0.20 (3.11) 0.14 (2.14) 0.13 (1.61) 0.19 (2.86) 
Model Fit 
Correlation (ρ) 0.04 -0.46* -0.50** 0.17 -0.44* 
N 3037 3037 3037 3034 2936 
*Parameter estimated to be significant at the 10% level.  **Parameter estimated to be significant at the 5% level.
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We show that the threat of severe adverse health consequences can induce significant 
improvements in diet quality (improvements from the perspective of the public health 
community, not from consumers’ perspectives). Cigarette smoking and dietary intake of 
cholesterol, total fat, and saturated fat are lower for those whose physicians told them they 
have high cholesterol, compared to those with undiagnosed high cholesterol. But, some also 
choose to compromise diet quality. We find that dietary intake of cholesterol is unaffected 
by the decision to take cholesterol-lowering medication. However, for those taking 
cholesterol-lowering medication, diets are higher in total fats and in saturated fats than are 
diets of those with unmedicated high cholesterol. The waist circumference of those on 
medication is also larger, although some of the increase may be associated with reduced 
cigarette consumption. The increased dietary intake of fat and saturated fat, along with 
increased waist size are telling evidence of offsetting behaviour, as medication lowers the 
health price of unhealthy choices. 
This suggests that, if life-threatening illnesses are not sufficient motivation for 
individuals to improve their diets and health behaviours, general public health admonitions 
to the population at large are unlikely to have much impact. The remaining policy question 
is whether those with high blood cholesterol are fully informed about the health benefits of 
medication. If individuals over assess the efficacy of medications, their utility maximizing 
choices could lead to diets and lifestyles that are even worse (for health) than the diets and 
lifestyles they chose before discovering their compromised health condition. In that case, 
the public health community could consider focusing attention on accurately portraying the 
health benefits of medication. 
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